Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CDC7 | O00311 | 5/20 | 0.60 |
| ▸ | STK3 | Q13188 | 5/20 | 0.60 |
| ▸ | MAP4K4 | O95819 | 4/20 | 0.60 |
| ▸ | PRKACA | P17612 | 4/20 | 0.60 |
| ▸ | GSK3B | P49841 | 4/20 | 0.60 |
| ▸ | CLK4 | Q9HAZ1 | 4/20 | 0.60 |
| ▸ | PRKD3 | O94806 | 3/20 | 0.60 |
| ▸ | CLK2 | P49760 | 3/20 | 0.60 |
| ▸ | GSK3A | P49840 | 3/20 | 0.60 |
| ▸ | CDK5 | Q00535 | 3/20 | 0.60 |
| ▸ | MAP4K2 | Q12851 | 3/20 | 0.60 |
| ▸ | ROCK1 | Q13464 | 3/20 | 0.60 |
| ▸ | DYRK1A | Q13627 | 3/20 | 0.60 |
| ▸ | KDR | P35968 | 3/20 | 0.60 |
| ▸ | ROCK2 | O75116 | 3/20 | 0.60 |
| ▸ | CDK2 | P24941 | 3/20 | 0.60 |
| ▸ | IRAK4 | Q9NWZ3 | 3/20 | 0.60 |
| ▸ | MARK3 | P27448 | 3/20 | 0.60 |
| ▸ | FLT3 | P36888 | 3/20 | 0.60 |
| ▸ | MELK | Q14680 | 3/20 | 0.60 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29377513 | 1.00 | CDC7 (0.60) | CDC7STK3MAP4K4PRKACAGSK3B | |
| SCHEMBL20119672 | 0.91 | SMN1; SMN2 (0.50) | CDC7STK3MAP4K4PRKACAGSK3B | |
| SCHEMBL22524256 | 0.82 | STK3 (0.68) | CDC7STK3MAP4K4PRKACAGSK3B | |
| SCHEMBL20119679 | 0.81 | SMN1; SMN2 (0.58) | KDRCDK1RPS6KB1AURKBAURKA | |
| SCHEMBL20119638 | 0.81 | SMN1; SMN2 (0.53) | GSK3BCDK5DYRK1ACDK2IRAK4 | |
| SCHEMBL2368308 | 0.78 | MAPK1 (0.65) | FGFR1MAPK1CDK8SMN1; SMN2ALOX15 | |
| SCHEMBL22524255 | 0.74 | STK3 (0.79) | CDC7STK3MAP4K4PRKACAGSK3B | |
| SCHEMBL17009429 | 0.74 | SMN1; SMN2 (0.52) | KDRCDK1RPS6KB1AURKBAURKA | |
| SCHEMBL12355042 | 0.73 | AURKA (0.65) | KDRLCKAURKAMAPK1CHEK1 | |
| SCHEMBL20119970 | 0.73 | SMN1; SMN2 (0.51) | CLK4CLK2DYRK1AKDRDYRK3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230279007-A1 | Compounds for Improving mRNA Splicing | THE UNITED STATES OF AMERICA, AS REPRESENTED BY THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES | 2023-09-07 | — | — | US | disclosed |
| US-20230279007-A1 | Compounds for Improving mRNA Splicing | THE UNITED STATES OF AMERICA, AS REPRESENTED BY THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES | 2023-09-07 | — | — | US | disclosed |
| US-11702417-B2 | Compounds for improving mRNA splicing | THE GENERAL HOSPITAL CORPORATION (US) | 2023-07-18 | — | — | US | disclosed |
| US-11702417-B2 | Compounds for improving mRNA splicing | THE GENERAL HOSPITAL CORPORATION (US) | 2023-07-18 | — | — | US | disclosed |
| US-20220162215-A1 | COMPOSITIONS AND METHODS OF USING THE SAME FOR TREATMENT OF NEURODEGENERATIVE AND MITOCHONDRIAL DISEASE | MITOKININ INC (US) | 2022-05-26 | — | — | US | disclosed |
| CN-114026093-A | Compositions for treating neurodegenerative and mitochondrial diseases and methods of use thereof | 麦托吉宁公司 | 2022-02-08 | — | — | CN | disclosed |
| WO-2020206363-A1 | COMPOSITIONS AND METHODS OF USING THE SAME FOR TREATMENT OF NEURODEGENERATIVE AND MITOCHONDRIAL DISEASE | MITOKININ,INC. (US) | 2020-10-08 | — | — | WO | disclosed |
| US-20200283441-A1 | Compounds for Improving mRNA Splicing | THE GENERAL HOSPITAL CORPORATION | 2020-09-10 | — | — | US | disclosed |
| US-10676475-B2 | Compounds for improving mRNA splicing | THE GENERAL HOSPITAL CORPORATION (US) | 2020-06-09 | — | — | US | disclosed |
| US-20180118748-A1 | Compounds for Improving mRNA Splicing | THE GENERAL HOSPITAL CORPORATION | 2018-05-03 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230279007-A1 | Compounds for Improving mRNA Splicing | RTCB, RBM17, HNRNPA2B1 | CDC7 1913/4885STK3 3318/4885MAP4K4 3650/4885 |
| US-10676475-B2 | Compounds for improving mRNA splicing | RTCB, RBM17, HNRNPA2B1 | CDC7 1913/4885STK3 3318/4885MAP4K4 3650/4885 |
| US-20180118748-A1 | Compounds for Improving mRNA Splicing | RTCB, RBM17, HNRNPA2B1 | CDC7 1913/4885STK3 3318/4885MAP4K4 3650/4885 |
| US-20220162215-A1 | COMPOSITIONS AND METHODS OF USING THE SAME FOR TREATMENT OF NEURODEGENERATIVE AND MITOCHONDRIAL DISEASE | NLN, PINK1, NME4 | CDC7 2140/4885STK3 818/4885MAP4K4 1177/4885 |
| US-11702417-B2 | Compounds for improving mRNA splicing | RTCB, RBM17, HNRNPA2B1 | CDC7 1913/4885STK3 3318/4885MAP4K4 3650/4885 |
| US-20200283441-A1 | Compounds for Improving mRNA Splicing | RTCB, RBM17, HNRNPA2B1 | CDC7 1913/4885STK3 3318/4885MAP4K4 3650/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.